Barrar Urges the PA Congressional Delegation to Demand Drug Approval for ALS Patients
HARRISBURG – In the near future, Rep. Steve Barrar (R-Chester/Delaware) plans to introduce a House resolution urging members of the Pennsylvania Congressional delegation to demand the approval of drug GM604 from the United States Food and Drug Administration (FDA) to help treat Amyotrophic Lateral Sclerosis (known as ALS or Lou Gehrig’s disease).

ALS, a progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord, has touched V. Michael Fulginiti, who previously lived in the 160th District, causing him to lose his ability to speak and swallow. In due time, the disease will progress, causing him to lose his ability to walk, stand upright, grab objects and any other independent function performed on a daily basis in everyday life and making him completely immobile and dependent.

“It is important that we give Mr. Fulginiti and the other 5,000 individuals across the United States a chance to fight and provide relief from a horrific, debilitating disease by approving GM604,” Barrar said.

GM604, currently a trial drug, has proven its ability to slow down, stop and even reverse the effects of ALS. Because the majority of ALS patients face certain paralysis and death, ALS presents a concrete case for GM604 to receive immediate approval by the United States FDA to treat the disease.

Just within the United States, more than 5,000 individuals are diagnosed annually with ALS. Currently in Pennsylvania, more than 1,000 individuals have been formally diagnosed with the disease.

Barrar hopes that a House resolution will signal the state House’s support to the Pennsylvania Congressional delegation.

Representative Stephen E. Barrar
160th District
Pennsylvania House of Representatives

Media Contact: Alison Evans
717.260.6206 /
Share |